Sustained Antitumor Immunity Based on Persistent Luminescence Nanoparticles for Cancer Immunotherapy

Wang, Ruoping; Shi, Junpeng; Liu, Song; Zheng, Shenghui; Liu, Xiaolong; Hong, Maochun; Zhang, Yun

doi:10.1002/adfm.202106884

Cited by 28 publications

(19 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CRT is a proapoptotic protein that can translocate to the cell membrane surface during ICD, acting as an “eat‐me” signal to elicit the antitumor immune response. [ 19 ] To monitor the surface‐exported CRT, 4T1 cells were cultured with 2 µ m ICy‐NLG for 2 h and then irradiated with 700‐nm light (50 mW cm −2 , 10 min) for immunofluorescence analysis. The CRT‐positive signal was observed in the ICy‐NLG ( L ) group ( Figure a), and the same result was obtained using flow cytometry analysis (Figure 3b).…”

Section: Resultsmentioning

confidence: 99%

Tumor Cell‐Responsive Photodynamic Immunoagent for Immunogenicity‐Enhanced Orthotopic and Remote Tumor Therapy

Chen

Xiong

Zhao

et al. 2022

Adv Healthcare Materials

View full text Add to dashboard Cite

Combining photodynamic therapy (PDT) and immune checkpoint blockades is an efficient method to maximize immunotherapeutic outcome by boosting tumor immunogenicity and modulating the immunosuppressive tumor microenvironment. However, the always‐on bioactivity of photosensitizers or immune checkpoint inhibitors leads to uncontrollable side effects, limiting the in vivo therapeutic efficacy of treatments. An activatable strategy is of great importance for improving the selectivity during cancer therapy. In this study, a photodynamic immunomodulator, ICy‐NLG, is developed by conjugating the photosensitizer ICy‐NH2 with the indoleamine 2,3‐dioxygenase 1 inhibitor NLG919 through a glutathione (GSH)‐cleavable linker to achieve activatable photodynamic immunotherapy. The conjugation considerably suppresses both the PDT effect and the activity of the inhibitor. After ICy‐NLG is activated by high levels of GSH in tumor cells, the PDT effect is restored and leads to immunogenic tumor cell death. The released tumor‐associated antigens in conjunction with the activated immune checkpoint inhibitor induce a synergistic antitumor immune response, resulting in the growth inhibition of primary and distant tumors and the prevention of lung metastasis in mouse xenograft models.

show abstract

Section: Resultsmentioning

confidence: 99%

Tumor Cell‐Responsive Photodynamic Immunoagent for Immunogenicity‐Enhanced Orthotopic and Remote Tumor Therapy

Chen

Xiong

Zhao

et al. 2022

Adv Healthcare Materials

View full text Add to dashboard Cite

show abstract

“…4 h. This phenomenon could be explained as the rapid release and slow transition of the stored excitation energy from the shallow and deep traps of mPL NPs, respectively. [28] In addition, the intensity was restored after LED illumination, and the cycled decaying and recharging of fluorescence intensities were observed without significant attenuation. As shown in Figure 2k, the emission spectrum of mPL overlapped with the absorption spectrum of Cy7, resulting in the FRET effect between the mPL donor and the Cy7 receptor.…”

Section: Characterization Of Mpl@pc-cy Npsmentioning

confidence: 94%

Persistent Luminescence‐Based Theranostics for Real‐Time Monitoring and Simultaneously Launching Photodynamic Therapy of Bacterial Infections

Zhang

Yan

Qiu

et al. 2022

Small

View full text Add to dashboard Cite

External light irradiation is usually required in bacterial infection theranostics; however, it is always accompanied by limited light penetration, imaging interference, and incomplete bacterial destruction. Herein, a feasible “image‐launching therapy” strategy is developed to integrate real‐time optical imaging and simultaneous photodynamic therapy (PDT) of bacterial infections into persistent luminescence (PL) nanoparticles (NPs). Mesoporous silica NPs are used as a substrate for in situ deposition of PL nanodots of ZnGa2O4:Cr3+ to obtain mPL NPs, followed by surface grafting with silicon phthalocyanine (Si‐Pc) and electrostatic assembly of cyanine 7 (Cy7) to fabricate mPL@Pc‐Cy NPs. The PL emission of light‐activated mPL@Pc‐Cy NPs is quenched by Cy7 assembly at physiological conditions through the fluorescence resonance energy transfer effect, but is rapidly restored after disassembly of Cy7 in response to bacterial infections. The self‐illuminating capabilities of NPs avoid tissue autofluorescence under external light irradiation and achieve real‐time colorimetric imaging of bacterial infections. In addition, the afterglow of mPL NPs can persistently excite Si‐Pc photosensitizers to promote PDT efficacy for bacterial elimination and accelerate wound full recovery with normal histologic features. Thus, this study expands the theranostic strategy for precise imaging and simultaneous non‐antibiotic treatment of bacterial infections without causing side effects to normal tissues.

show abstract

“…Summary of polysaccharide-based stimulus-responsive nanomedicines for combination cancer immunotherapy (Abbreviations: hyaluronic acid (HA); mitoxantrone (MIT); hydralazine (HYD); framework-8 (ZIF-8); cisplatin (CDDP); plasmid encoding IL-12 gene (pIL-12); polymetformin polymer (polyMET); doxorubicin (DOX); resiquimod (R848); poly(L-histidine) (PHIS); oxaliplatin (OXA); indocyanine green (ICG); mitoxantrone (MTO); metal-organic framework (MIL-100); polydopamine (PDA); immunogenic cell death-inducer (IR780); chloroquine (CQ); vibrio vulnificus flagellin B (FlaB); ovalbumin (OVA); gold nanoparticle (AuNPs); black phosphorus (BP); silicon phthalocyanine (Si-Pc); The MOF nanoparticles PCN224 (named as PCN); acriflavine (ACF); matrix metalloproteinase sensitive peptide (CPLGLAGG); A powerful autophagy inducer (STF-62247); tridecapeptide (GTFGFRRRRRRRR, termed as TFG peptide); celastrol (CLT); 1-methyltryptophan (1-MT); glutathione (GSH); PD-1 antagonist peptides (A12 peptides); paclitaxel (PTX); imiquimod (IMQ); programmed cell death ligand 1 (shPD-L1); polyethylenimine (PEI); camptothecin (CPT); imiquimod (R837); polyaniline (PANi); chlorin e6 (Ce6); anti-PD-L1 monoclonal antibodies (aPD-L1); indoleamine 2,3-dioxygenase (IDO) inhibitor (NLG919); small molecule inhibitor BMS 202 (BMS); MMP-9 sensitive peptide (Mal-GPLGLK-Mal); pH-sensitive hyaluronic acid-acetal-PTX prodrugs (HA-ace-PTX(SH)); celecoxib (CXB); 3-diethylaminopropyl isothiocyanate (DEAP); matrix metalloproteinase-2 peptide (MMP-2 peptide); lonidamine (LND); LND dimer(d-LND); curcumin (CUR); poly (acrylamide-co-acrylonitrile-co-vinylimidazole-co-bis(2-methacryloyl) oxyethyl disulfide) (PAAVB); reactive oxygen species (ROS); 4-(hydroxymethyl) benzoate borate (PBAP); inhibitor of κB kinase β (IKKβ)-siRNA (IKKβ-siRNA); ocarboxymethyl-chitosan (CMCS); sorafenib (SF); TAM re-polarization agents (IMD-0354); glycol chitosan (GC); modified Indocyanine green (IR 820); cytosineguanine (CpG); hollow CuS nanomedicines (HCuSNPs); polyi-nosinic:polycytidylic acid (poly I:C); programmed death ligand 1(PD-L1); 4-nitrophenyl-4-(4,4,5,5tetramethyl-1,3,2-dioxaborolan-2-yl) benzyl carbonate (NBC); docetaxel (DTX); D-α-tocopheryl succinate (TOS); low molecular weight heparin (LMWH); epacadostat (EPA); HP-coated blank liposome(HP/L); hyaluronidase (HAase); acetalated dextran (AcDEX); Nutlin-3a (Nut3a); granulocyte-macrophage colony-stimulating factor (GM-CSF); interleukin-2 (IL-2); dimethylmaleic anhydride modified polyethyleneimine (PEI-DMMA); poly-2-(diethylamino)-ethyl acrylate (PDEA); benzimidazole (BM); ATP-specific aptamer (Aapt); lipopolysaccharide (LPS); verteporfin (VP); amphoteric methacrylamide N-carboxyethyl chitosan (CECm); nanoparticles of spermine modified acetylated dextran loaded Nut3a (Sp-AcDEX); pheophorbide A (PPa); A prodrug of bromodomain-containing protein 4 inhibitor (BRD4i) (JQ1); ferrocene (Fc); TGF-β receptor inhibitor (SB431542); checkpoint inhibitor anti-CTLA4 antibody (aCTLA4); zinc phthalocyanine (ZnPc). HA-DOX/PHIS/R848 NPs DOX, R848 Hydrazone bond, PHIS [31] Light OIMH NPs OXA, ICG ICG [32] MMH NPs MTO, MIL-100 MIL-100 [33] CPG@DOX@PDA hydrogel CpG-ODN, DOX, PDA PDA [34] PPP/CpG/HA CpG ODN, PDA PDA [35] HIF FlaB, IR780 IR780 [36] HA-OVA-AuNPs OVA, AuNPs AuNPs [37] HA-BP HA, BP BP [38] ZGS-Si-Pc@HA Si-Pc Si-Pc [39] PCN-ACF-CpG@HA CpG, PCN, ACF PCN …”

Section: Regulates Body's Immunitymentioning

confidence: 99%

“…In 4T1 tumor-bearing mice, ZGS-Si-Pc@HA greatly reduced primary and distant tumors, with long-term immune memory benefits (Figure 2H-J). [39] Moreover, Cai et al obtained nanoparticles with porous structures by the self-assembly of H2TCPP (a photosensitizer) and zirconium ions. Then HA-coated PCN-ACF-CpG@HA nanomedicines were prepared by simultaneously loading HIF signaling inhibitor (ACF) and immunoadjuvant Cytosineguanine (CpG) (Figure 3A).…”

mentioning

confidence: 99%

Polysaccharide‐Based Stimulus‐Responsive Nanomedicines for Combination Cancer Immunotherapy

Liu

Yan

et al. 2023

Small

View full text Add to dashboard Cite

According to the World Health Organization, there were approximately 9.96 million deaths from cancer in 2020. Although researchers are actively searching for new treatments, the outcomes have been unsatisfactory, with limited improvement in the five-year survival rates. [2] Until now, immunotherapy has become one of the four pillars of clinical cancer treatment, along with surgery, chemotherapy, and radiotherapy. [3] It endows the body with the ability to eliminate tumors and prevent recurrence by stimulating the immune system, thus extending the survival time of patients. [4] Checkpoint inhibitors, pericyte therapy, lymphocyte-promoting cytokines, agonistic antibodies against co-stimulatory receptors, and cancer vaccines have been developed in recent years. [5] Due to the limited targeting and inherent toxicity of immune medicines, systemic use may result in autoimmune illness or non-specific inflammation. [6,7] In addition, tumor heterogeneity, clonal diversity, complex genetic mutations, and complex microenvironment all contribute to the poor outcomes of current tumor treatments. [8,9] Fortunately, previous studies have demonstrated that chemotherapy, photodynamic therapy (PDT), and photothermal therapy (PTT) can induce immunogenic cell death (ICD), which can enhance the immunotherapy effect. [10,11] However, the precise delivery of the co-therapeutic agents to the tumor site becomes the main challenge. [12] The rapid development of nanotechnology has promoted the application of nanomedicines in tumor therapy. [13] Nanomedicines can accumulate at tumor sites via the enhanced permeability and retention (EPR) effect and deliver drugs to specific tumor cells, thereby reducing off-target toxicity. [14,15] Notably, stimulus-responsive nanomedicines as a promising drug delivery method have received more and more attention. [16,17] The smart nano-platforms can achieve rapid drug release in response to external stimulus (ultrasound, mechanical stimuli, magnetic fields, lasers, etc.) or internal stimulus in the tumor microenvironment (TME) (weak acidity, high glutathione (GSH) levels, reactive oxygen species (ROS), enzymes, adenosine triphosphate (ATP), etc.), thus improving tumor treatment outcomes. [18] Polysaccharides, a family of potential biomaterials, possess unique advantages such as unique physicochemical properties, Cancer immunotherapy is a promising antitumor approach, whereas nontherapeutic side effects, tumor microenvironment (TME) intricacy, and low tumor immunogenicity limit its therapeutic efficacy. In recent years, combination immunotherapy with other therapies has been proven to considerably increase antitumor efficacy. However, achieving codelivery of the drugs to the tumor site remains a major challenge. Stimulus-responsive nanodelivery systems show controlled drug delivery and precise drug release. Polysaccharides, a family of potential biomaterials, are widely used in the development of stimulus-responsive nanomedicines due to their unique physicochemical properties, biocompatibility, and modifiab...

show abstract

Sustained Antitumor Immunity Based on Persistent Luminescence Nanoparticles for Cancer Immunotherapy

Cited by 28 publications

References 52 publications

Tumor Cell‐Responsive Photodynamic Immunoagent for Immunogenicity‐Enhanced Orthotopic and Remote Tumor Therapy

Tumor Cell‐Responsive Photodynamic Immunoagent for Immunogenicity‐Enhanced Orthotopic and Remote Tumor Therapy

Persistent Luminescence‐Based Theranostics for Real‐Time Monitoring and Simultaneously Launching Photodynamic Therapy of Bacterial Infections

Polysaccharide‐Based Stimulus‐Responsive Nanomedicines for Combination Cancer Immunotherapy

Contact Info

Product

Resources

About